Which antibiotic wins the battle against chlamydia in teens?
NCT ID NCT00980148
First seen Aug 05, 2026 · Last updated Aug 06, 2026 · Updated 1 time
Summary
This trial tests two approved antibiotics—azithromycin (a single dose) and doxycycline (twice daily for a week)—to see which is more effective at curing genital chlamydia in young people aged 12-21 living in youth correctional facilities. Participants provide urine samples over about two months to check if the infection clears. The goal is to find the best treatment to prevent reinfection and serious health issues.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- azithromycin and doxycycline
- What this could lead to
- If one treatment proves more effective, it could become the preferred option for curing chlamydia and preventing serious health problems in young people.
- What could go wrong
- This is a Phase 3 trial, but results may not apply to all populations. Some people may still get reinfected, and side effects are possible.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHLAMYDIAL INFECTION are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Los Angeles County Department of Public Health - Sexually Transmitted Disease Program
Los Angeles, California, 90007-2608, United States
-
University of Alabama Hospital - Infectious Diseases
Birmingham, Alabama, 35249-0001, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.